MSB 0.00% $1.15 mesoblast limited

Alzheimer drug approved, page-59

  1. 74 Posts.
    lightbulb Created with Sketch. 44
    I'd be really interested to know what@otherperspective and other posters more knowledgeable than I think about whether this Aducanumab approval changes the approval prospects for our treatments. I wonder if the SP appreciation today is as a result of this with investors thinking this signals a new approach from the FDA.

    • Does it suggest a shift in approach from the FDA or should it be viewed in isolation?
    • Did its phase III trial miss primary end point? And was it approved on secondary endpoints?
    • What about the black letter law approach to MOA in the FDA hearing re Ryoncil? Is that out the window too, or are we reading too much into a single decision by a big cumbersome and capricious agency?
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.15
Change
0.000(0.00%)
Mkt cap ! $1.304B
Open High Low Value Volume
$1.15 $1.17 $1.13 $3.335M 2.908M

Buyers (Bids)

No. Vol. Price($)
2 3905 $1.21
 

Sellers (Offers)

Price($) Vol. No.
$1.10 141 1
View Market Depth
Last trade - 15.59pm 22/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.